Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

The autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell product, lisocabtagene maraleucel (liso‐cel), is administered at equal target doses of CD8(+) and CD4(+) CAR(+) T cells. This analysis assessed safety and efficacy of liso‐cel in Japanese patients with relapsed or refractory (R/R) aggre...

Descripción completa

Detalles Bibliográficos
Autores principales: Makita, Shinichi, Yamamoto, Go, Maruyama, Dai, Asano‐Mori, Yuki, Kaji, Daisuke, Ananthakrishnan, Revathi, Ogasawara, Ken, Stepan, Lara, Schusterbauer, Claudia, Rettby, Nils, Hasskarl, Jens, Izutsu, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761090/
https://www.ncbi.nlm.nih.gov/pubmed/35619325
http://dx.doi.org/10.1002/cam4.4820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761090/
https://www.ncbi.nlm.nih.gov/pubmed/35619325
http://dx.doi.org/10.1002/cam4.4820

Ejemplares similares